ZUMA-2 cohorts drive brexu-cel’s journey in relapsed/refractory mantle cell lymphoma, from high response rates to dose ...
Among 5-year survivors in the tebentafusp arm, 44% received tebentafusp as their only therapy. In contrast, 86% of control ...
Sikander Ailawadhi, MD discusses the positive sentiments on subcutaneous isatuximab from European regulators and patient ...
New in the NCCN guidelines is lurbinectedin [Zepzelca] and atezolizumab [Tecentriq] maintenance. 2 There are other ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results